Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
St. Jude Children's Research Hospital
GlaxoSmithKline
National Cancer Institute (NCI)
Institut Bergonié
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Institut Bergonié
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eisai Inc.
Children's Oncology Group
Hutchmed
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Cellestia Biotech AG
Stanford University
Bayer
Stanford University
Children's Oncology Group
Sarcoma Alliance for Research through Collaboration
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Y-mAbs Therapeutics
St. Jude Children's Research Hospital
City of Hope Medical Center
Eisai Inc.
Massachusetts General Hospital
Children's Oncology Group
Northwestern University
BTG International Inc.
National Cancer Institute (NCI)
The Hospital for Sick Children
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Barbara Ann Karmanos Cancer Institute
Isofol Medical AB